The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | ASH highlights: results of the TRIANGLE study in MCL
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, comments on recent developments in non-Hodgkin lymphoma (NHL) presented at ASH 2022, highlighting the TRIANGLE study (NCT02858258), which assessed ibrutinib combined with standard chemoimmunotherapy or as a substitute for autologous stem cell transplantation (ASCT) in younger patients with mantle cell lymphoma (MCL). The trial reported superior progression-free-survival (PFS) in groups treated with ibrutinib. Prof. Vitolo suggests that this is likely to have a significant impact on clinical practice. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Seagen, Genmab, Incyte, Costellation, Bayer, Regeneron: Consultancy; AbbVie, Incyte, Janssen, Gilead Sciences: Speakers Bureau.
